Text Size

Evaluation of an Electro-stimulator for the Treatment of Xerostomia (GenNarino)

This study has been completed.
Sponsor:
Collaborators:
Universidad El Bosque, Bogotá
Charite University, Berlin, Germany
University of Zagreb
McGill University
Istanbul University
Hebrew University of Jerusalem
Universita degli Studi di Palermo
Universidad Nacional Autonoma de Mexico
Skane University Hospital
University of Brasilia
Hospital San Carlos, Madrid
University of Kentucky
Helsinki University
Indiana University
Information provided by:
Saliwell Ltd.
ClinicalTrials.gov Identifier:
NCT00509808
First received: July 31, 2007
Last updated: April 5, 2010
Last verified: April 2010
History of Changes
  Purpose

This is a multinational trial, aimed at testing the safety and performance of a electrostimulating device ("GenNarino") to treat dry mouth, over one year. The design is as follows:

  • Multi-center, double blind, sham (placebo) controlled, about 10 xerostomia patients per center
  • Patients receive a GenNarino (and its remote control) that is programmed for one month sham and one month active mode (the order of which is randomly assigned), and thereafter 9 months at the active mode (divided in period of 3 months, the order of each is randomly assigned at wearing GenNarino for 1, 5 or 10 minutes at a time).

Study hypothesis: Gennarino will lead to significant symptomatic improvement

- At the clinic: monthly examinations at the first 2 months, and then every 3 months, including whole saliva collection and questionnaire; at the first visit impression taking for GenNarino preparation


Condition Intervention Phase
Xerostomia
 Device: Electrostimulation
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Performance Evaluation of an Electro-stimulator Mounted on an Intra-oral Removable Appliance (Saliwell GenNarino) for the Treatment of Xerostomia

Resource links provided by NLM:

MedlinePlus related topics: Dry Mouth
U.S. FDA Resources

Further study details as provided by Saliwell Ltd.:

Primary Outcome Measures:
  • Significant symptomatic improvement [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • 1- Increased salivary output 2- Event free use (no adverse side-effects) [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: January 2007
Study Completion Date: April 2010
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: electrostimulation
Use of device for predetermined length
 Device: Electrostimulation
  1. 1st month GN wearing (activated or sham mode)
  2. 2nd month wearing (opposite mode)
  3. 3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes
  4. 6th - 8th month: activated GN wearing for 1, 5 or 10 minutes
  5. 9th - 11th month: activated GN wearing for 1, 5 or 10 minutes
Other Name: GenNarino

Detailed Description:

The clinical trial, titled "Safety and performance evaluation of an electro-stimulator mounted on an intra-oral removable appliance (GenNarino) for the treatment of xerostomia" is a prospective, randomized, double-blind, sham-controlled multi-center trial, followed by an open-label study. Study subjects are patients with xerostomia. The purpose of the trial is to test the safety and efficacy of electrostimulation using the GenNarino device.

The primary endpoint is significant symptomatic improvement, and the secondary ones, increased salivary output and event free use (no adverse side-effects). The clinical follow-up consists of periodic clinical examinations.

In this clinical trial the use of the device is compared between active vs. sham mode for one month each in a double-blind design (Stage I). Thereafter, at Stage II the xerostomia relieving effect of the active device is assessed in an open label design for additional 6 months. Clinic- and home-based questionnaires and whole saliva collections are performed.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The patient must be at least 18 years of age.

  2. The patient must have clinical symptoms of xerostomia (dry mouth) due to

    • Primary or secondary Sjögren's syndrome
    • Medication intake
    • Head and neck radiation with survival expectancy of more than one year
    • Chronic graft vs. host disease with survival expectancy of more than one year
  3. Patients are requested not to take systemic sialogogues during the first 2 months of the study (when active is tested vs. sham)
  4. Female patients of child bearing potential must have a negative pregnancy test within twenty-four hours of enrollment.
  5. The patient must understand and consent in writing to the procedure.
  6. The patient agrees to undergo all examinations and clinical evaluations planned for the study.

Exclusion Criteria:

  1. Active HIV or HCV infection
  2. Severe systemic disease
  3. Known allergy to materials similar to be used in the investigational product
  4. Known mental disease

  5. Presence of depression, by positive answers to both the following questions:

    • "During the past month have you often been bothered by feeling down, depressed or hopeless?"
    • "During the past month have you often been bothered by little interest or pleasure in doing things?"
  6. Patients wearing other active implants like pacemaker or defibrillator
  7. Patients with poor oral hygiene
  8. Patients whose oral anatomical characteristics precludes the insertion of the device
  9. Patients who are unable or unwilling to cooperate with study procedures.
  10. Pregnancy
  11. Presence of erosive or ulcerative oral lesions, which are chronic or recurrent, such as erosive lichen planus, RAS, eryth. Candidosis, and of suspected pre-malignant or malignant lesions
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00509808

Locations
Finland
Helsinki University Central Hospital and University of Helsinki
Helsinki, Finland, 00014
Sponsors and Collaborators
Saliwell Ltd.
Universidad El Bosque, Bogotá
Charite University, Berlin, Germany
University of Zagreb
McGill University
Istanbul University
Hebrew University of Jerusalem
Universita degli Studi di Palermo
Universidad Nacional Autonoma de Mexico
Skane University Hospital
University of Brasilia
Hospital San Carlos, Madrid
University of Kentucky
Helsinki University
Indiana University
Investigators
Study Director: Andy Wolff, DMD Saliwell Ltd.
  More Information

No publications provided by Saliwell Ltd.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Dr. Andy Wolff, Saliwell Ltd.
ClinicalTrials.gov Identifier: NCT00509808     History of Changes
Other Study ID Numbers: 1-Wolff
Study First Received: July 31, 2007
Last Updated: April 5, 2010
Health Authority: Canada: Ethics Review Committee
Colombia: Institutional Review Board
Finland: Ethics Committee
Germany: Ethics Commission
Israel: Ministry of Health
Italy: Ethics Committee
Spain: Ethics Committee
Sweden: Institutional Review Board
Turkey: Ethics Committee
United States: Institutional Review Board

Additional relevant MeSH terms:
Xerostomia
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases

ClinicalTrials.gov processed this record on May 22, 2013